Full-year 2025 net loss was $119.9 million, up from $86.5 million in 2024. Fourth quarter 2025 net loss was $33.8 million, up from $25.6 million in Q4 2024. Cash, cash equivalents, and marketable securities totaled $256.0 million as of December 31, 2025. Current cash is expected to fund operations through at least 2027. Launched dabogratinib 3x3 strategy focusing on 3 late-stage clinical studies (LG-UTUC, IR NMIBC, ACH) for 3 potential blockbuster indications. Prioritized portfolio by exiting metastatic bladder cancer to focus resources. Anticipates dosing first patient in Phase 2 LG-UTUC study (SURF303) in 2026. Expects initial three-month complete response data from Phase 2 IR NMIBC study (SURF302) by end of 1H 2026. Expects interim results from Phase 2 ACH study (BEACH301) safety sentinel cohort in 2H 2026, including 6-month average height velocity data. Strengthened leadership team with new Chief Operating Officer and Chief Regulatory Officer.